Skip to main content
. 2018 Apr 5;13(4):e0193550. doi: 10.1371/journal.pone.0193550

Fig 6.

Fig 6

Correlation analyses: Life time exposure to Lyso-Gb3 ([Lyso-Gb3]*age) and: clinical severity, (MSSI) for: (A) N215S males (n = 13), (B) non-N215S males (n = 9), (C) N215S females (n = 26), and (D) non-N215S females (n = 36); baseline GFR for: (E) N215S males (n = 13), (F) non-N215S males (n = 9), (G) N215S females (n = 26), and (H) non-N215S females (n = 33); LVMI for: (I) N215S males (n = 12), (J) non-N215S males (n = 9), (K) N215S females (n = 23), and (L) non-N215S females (n = 34); ns = not significant.